PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Status:
RECRUITING
Trial end date:
2027-10-10
Target enrollment:
Participant gender:
Summary
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.